Home
Products
Learn
About
Pricing
Log In
Back
TEG
Asset Logo

Triangle Energy (Global) Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

โšก๏ธ ENERGY

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

-18.97%
Annual Growth

5 years average annual capital growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

2
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Triangle Energy (Global) Ltd. engages in the exploration and production of oil and gas. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-01-06. The firm is focused on the production and selling of oil from its Cliff Head producing oil field. Its projects include the Cliff Head oil field, PL231 conventional gas project, and Mount Horner project. The company holds approximately 78.75% interest in the producing Cliff Head Oil Field (WA-31-L) located in the Perth Basin. The Cliff Head Oil Field (Cliff Head) is located approximately 300 kilometers north of Perth and 12 kilometers off the coast of Dongara in Western Australia under Production License WA-31-L (WA-31-L Permit). The company has a 50% interest in the P2628 license comprising four blocks containing the Cragganmore gas field. The firm has equity interest in State Gas Ltd, which has 100% operating interest in the Reids Dome production license (PL 231) in Queensland. The company also has a 50% share of the Mt Horner L7 production license and the adjacent EP 437 exploration license, both located in the Perth Basin.

๐Ÿ“ˆ Performance

Price History

+100.00%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.00

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in TEG

2

๐Ÿ“Š Total Capital Earnings

$6K

๐Ÿ”ƒ Average investment frequency

21 weeks

๐Ÿ’ต Average investment amount

$795

โฐ Last time a customer invested in TEG

123 days
TEG investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

100%

50k - 100k

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

50%

35 - 90

50%
๐Ÿ™‹ Legal gender of investors

Female

Male

100%

Pearlers who invest in TEG also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

7.85%

๐Ÿ“Š Share price

$106.09 AUD

๐Ÿ‡ฆ๐Ÿ‡บ AUSTRALIA

๐Ÿงฑ MATERIALS

๐Ÿ’ธ FINANCIALS

โ›ณ๏ธ DIVERSIFIED

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

15.63%

๐Ÿ“Š Share price

$139.32 AUD

๐ŸŒ GLOBAL

๐Ÿค– TECHNOLOGY

โ›ณ๏ธ DIVERSIFIED

๐Ÿ“ˆ HIGH PRICE GROWTH

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as โ€œClimate Leadersโ€ that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

๐Ÿ™Œ Performance (5Yr p.a)

9.05%

๐Ÿ“Š Share price

$15.57 AUD

๐ŸŒ GLOBAL

๐Ÿค– TECHNOLOGY

โ›ณ๏ธ DIVERSIFIED

๐Ÿ“ˆ HIGH PRICE GROWTH

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

๐Ÿ™Œ Performance (5Yr p.a)

20.36%

๐Ÿ“Š Share price

$61.33 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿ’ฐ HIGH DIVIDEND

๐Ÿ‡บ๐Ÿ‡ธ UNITED STATES

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyโ€™s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

๐Ÿ™Œ Performance (5Yr p.a)

-11.76%

๐Ÿ“Š Share price

$0.01 AUD

๐Ÿงฌ BIOTECHNOLOGY

Want more shares? Try these...

๐Ÿ“Š Share price

$0.03 AUD
Compare
Add to watchlist